Skip to main content
HR 3689 110th Congress House Health Blood banks Clinical trials Data banks Economics and Public Finance Epidemiology Federal advisory bodies Federal aid to health facilities Federal aid to research Government Operations and Politics Laboratories Medical research Medical screening Medical statistics Medical tests Nonprofit organizations Ovarian cancer Research centers Research grants Risk

Ovarian Cancer Biomarker Research Act of 2007

Introduced: September 27, 2007 See on congress.gov
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 8, 2007
Referred to the Subcommittee on Health.
Sep 28, 2007
Sponsor introductory remarks on measure. (CR E2019-2020)
Sep 27, 2007
Referred to the House Committee on Energy and Commerce.
Sep 27, 2007
Introduced in House
 Plain-English summary Congressional Research Service

Ovarian Cancer Biomarker Research Act of 2007 - Amends the Public Health Service Act to require the Director of the National Cancer Institute to enter into cooperative agreements with, or make grants to, public or nonprofit entities to establish and operate centers to conduct research on biomarkers for use in risk stratification for, and the early detection and screening of, ovarian cancer. Designates each center as an Ovarian Cancer Biomarker Center of Excellence.

Allows federal payments under such an agreement or grant to be used for research on: (1) the development and characterization of new biomarkers and the refinement of existing biomarkers; (2) the clinical and laboratory validation of such biomarkers; (3) the development and implementation of clinical and epidemiological research on the utilization of such biomarkers; and (4) the development and implementation of repositories for new tissue, urine, serum, and other biological specimens.

Requires the Director to: (1) make available for research banked serum and tissue specimens from clinical research regarding ovarian cancer that was funded by the Department of Health and Human Services (HHS); (2) establish an Ovarian Cancer Biomarker Clinical Trial Committee to assist the Director to design and implement national clinical trials to determine the utility of such biomarkers; and (3) establish a national data center to conduct statistical analyses of trial data.

What's happening now November 8, 2007

Referred to the Subcommittee on Health.

 Committees of jurisdiction 2